OncoMatch/Clinical Trials/NCT07139873
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Is NCT07139873 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including DZD8586 and Bendamustine for chronic lymphocytic leukemia/small lymphocytic lymphoma.
Treatment: DZD8586 · Bendamustine · Idelalisib · Rituximab — This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Adequate bone marrow reserve
Kidney function
Adequate organ system functions
Liver function
Adequate organ system functions
Adequate bone marrow reserve and organ system functions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify